

List of Publications

1. Zang J, Wang G, Zhao T, Liu H, Lin X, Yang Y, Shao Z, Wang C, Chen H, Chen Y, Zhu Z, Miao W, Chen X, **Zhang J**. A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [¹⁷⁷Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer. *Eur J Nucl Med Mol Imaging*. 2023 Oct 21. doi: 10.1007/s00259-023-06470-3. Epub ahead of print. PMID: 37864592.
2. Fu H, Huang J, Zhao T, Wang H, Chen Y, Xu W, Pang Y, Guo W, Sun L, Wu H, Xu P, Su B, **Zhang J**, Chen X, Chen H. Fibroblast Activation Protein-Targeted Radioligand Therapy with ¹⁷⁷Lu-EB-FAPI for Metastatic Radioiodine Refractory Thyroid Cancer: First-in-Human, Dose-Escalation Study. *Clin Cancer Res*. 2023 Oct 6. doi: 10.1158/1078-0432.CCR-23-1983. Epub ahead of print. PMID: 37801296.
3. Wu Q, Zhang Y, Jia G, Hou M, Jiang Y, Wei W, Liu P, Huang G, Zou J, **Zhang J**, Hai W, Zhang M, Li B, Chen X, Zhang C. A sequential dual-locked strategy with pH-responsive activation of photosensitizers and precise Cerenkov radiation delivery for cancer theranostics. *Nano Today*. 2023 Oct; 52: 101984.
4. Zang J, Lin R, Wen X, Wang C, Zhao T, Jakobsson V, Yang Y, Wu X, Guo Z, Chen X, **Zhang J**, Miao W. A Head-to-Head Comparison of ⁶⁸Ga-LNC1007 and 2-¹⁸F-FDG/⁶⁸Ga-FAPI-02 PET/CT in Patients With Various Cancers. *Clin Nucl Med*. 2023 Oct 1;48(10):861-868. doi: 10.1097/RLU.0000000000004820. Epub 2023 Sep 2. PMID: 37682601.
5. Lin R, Wang C, Chen S, Lin T, Cai H, Chen S, Yang Y, **Zhang J**, Xu F, Zhang J, Chen X, Zang J, Miao W. [⁶⁸Ga]Ga-LNC1007 PET/CT in the evaluation of renal cell carcinoma: comparison with 2-¹⁸F]FDG/[⁶⁸Ga]Ga-PSMA PET/CT. *Eur J Nucl Med Mol Imaging*. 2023 Sep 20. doi: 10.1007/s00259-023-06436-5. Epub ahead of print. PMID: 37728667.
6. Tao Y, Jakobsson V, Chen X, **Zhang J**. Exploiting Albumin as a Versatile Carrier for Cancer Theranostics. *Acc Chem Res*. 2023 Sep 19;56(18):2403-2415. doi: 10.1021/acs.accounts.3c00309. Epub 2023 Aug 25. PMID: 37625245.
7. Qiao X, Gu X, Liu Y, Shu X, Ai G, Qian S, Liu L, He X, **Zhang J**. MRI Radiomics-Based Machine Learning Models for Ki67 Expression and Gleason Grade Group Prediction in Prostate Cancer. *Cancers (Basel)*. 2023 Sep 13;15(18):4536. doi: 10.3390/cancers15184536. PMID: 37760505; PMCID: PMC10526397.
8. **Zhang J**, Zhao T, Jakobsson V, Chen X. Clinical translation of radiotheranostics for precision oncology. *Nature Reviews Bioengineering*. 2023 Aug 25;1:612-614.
9. Ruan D, Zhao L, Cai J, Xu W, Sun L, Li J, **Zhang J**, Chen X, Chen H. Evaluation of FAPI PET imaging in gastric cancer: a systematic review and meta-analysis. *Theranostics*. 2023 Aug 21;13(13):4694-4710. doi: 10.7150/thno.88335. PMID: 37649615; PMCID: PMC10465231.

10. **Zhang J**, Schuchardt C, Chen X, Baum RP. Rapid Tumor Washout of ¹⁷⁷Lu-PSMA Radioligand in Renal Cell Carcinoma. *Clin Nucl Med*. 2023 Aug 1;48(8):732-734. doi: 10.1097/RLU.0000000000004725. Epub 2023 Jun 3. PMID: 37276536.
11. Wang P, Li T, Li F, **Zhang J**, Jing H. Bladder paraganglioma detection with [¹⁸F]MFBG PET/CT: a superior alternative to [⁶⁸Ga]Ga-DOTATATE. *Eur J Nucl Med Mol Imaging*. 2023 Aug;50(10):3147-3148. doi: 10.1007/s00259-023-06233-0. Epub 2023 Apr 22. PMID: 37086274.
12. Wen X, Xu P, Zeng X, Liu J, Du C, Zeng X, Cheng X, Wang X, Liang Y, Zhao T, Yang H, Li H, Meng L, Fang J, Liu H, Zhou Z, **Zhang J**, Zhang X, Guo Z, Chen X. Development of [¹⁷⁷Lu]Lu-LNC1003 for radioligand therapy of prostate cancer with a moderate level of PSMA expression. *Eur J Nucl Med Mol Imaging*. 2023 Jul;50(9):2846-2860. doi: 10.1007/s00259-023-06229-w. Epub 2023 Apr 25. PMID: 37097443.
13. Jiang Y, Liu Q, Wang G, **Zhang J**, Zhu Z, Chen X. Evaluation of Safety, Biodistribution, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog ¹⁷⁷Lu-DOTA-EB-TATE With and Without Amino Acid Infusion. *Clin Nucl Med*. 2023 Jun 1;48(6):e289-e293. doi: 10.1097/RLU.0000000000004642. Epub 2023 Apr 18. PMID: 37075254.
14. Wang R, Jakobsson V, Wang J, Zhao T, Peng X, Li B, Xue J, Liang N, Zhu Z, Chen X, **Zhang J**. Dual targeting PET tracer [⁶⁸Ga]Ga-FAPI-RGD in patients with lung neoplasms: a pilot exploratory study. *Theranostics*. 2023 May 15;13(9):2979-2992. doi: 10.7150/thno.86007. PMID: 37284441; PMCID: PMC10240811.
15. Zhang Y, Wang L, Zhang C, **Zhang J**, Yuan L, Jin S, Zhou W, Guan X, Kang P, Zhang C, Tian J, Chen X, Li D, Jia W. Preclinical assessment of IRDye800CW-labeled gastrin-releasing peptide receptor-targeting peptide for near infrared-II imaging of brain malignancies. *Bioeng Transl Med*. 2023 May 9;8(4):e10532. doi: 10.1002/btm2.10532. PMID: 37476052; PMCID: PMC10354759.
16. Zhao L, Wen X, Xu W, Pang Y, Sun L, Wu X, Xu P, **Zhang J**, Guo Z, Lin Q, Chen X, Chen H. Clinical Evaluation of ⁶⁸Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin $\alpha\beta 3$ in Various Cancer Types. *J Nucl Med*. 2023 May 4;jnumed.122.265383. doi: 10.2967/jnumed.122.265383. Epub ahead of print. PMID: 37142301.
17. Wang P, Li T, Li F, Zhang J, Jing H. Bladder paraganglioma detection with [¹⁸F]MFBG PET/CT: a superior alternative to [⁶⁸Ga]Ga-DOTATATE. *Eur J Nucl Med Mol Imaging*. 2023 Aug;50(10):3147-3148. doi: 10.1007/s00259-023-06233-0. Epub 2023 Apr 22. PMID: 37086274.
18. Wang G, Zang J, Jiang Y, Liu Q, Sui H, Wang R, Fan X, **Zhang J**, Zhu Z, Chen X. A Single-Arm, Low-Dose, Prospective Study of ¹⁷⁷Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer. *J Nucl Med*. 2023 Apr;64(4):611-617. doi: 10.2967/jnumed.122.264857. Epub 2022 Nov 3. PMID: 36328486

19. Liu Q, Kulkarni HR, Zhao T, Schuchardt C, Chen X, Zhu Z, **Zhang J**, Baum RP. Peptide Receptor Radionuclide Therapy in Patients With Advanced Progressive Medullary Thyroid Cancer: Efficacy, Safety, and Survival Predictors. *Clin Nucl Med*. 2023 Mar 1;48(3):221-227. doi: 10.1097/RLU.0000000000004539. Epub 2023 Jan 12. PMID: 36723881.
20. Pang Y, Zhao L, Meng T, Xu W, Lin Q, Wu H, **Zhang J**, Chen X, Sun L, Chen H. PET Imaging of Fibroblast Activation Protein in Various Types of Cancer Using ⁶⁸Ga-FAP-2286: Comparison with ¹⁸F-FDG and ⁶⁸Ga-FAPI-46 in a Single-Center, Prospective Study. *J Nucl Med*. 2023 Mar;64(3):386-394. doi: 10.2967/jnumed.122.264544. Epub 2022 Sep 2. PMID: 36215571; PMCID: PMC10071807.
21. Shi M, Jakobsson V, Greifenstein L, Khong PL, Chen X, Baum RP, **Zhang J**. Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists. *Front Med (Lausanne)*. 2022 Dec 7;9:1034315. doi: 10.3389/fmed.2022.1034315. PMID: 36569154; PMCID: PMC9767967.
22. Zang J, Wen X, Lin R, Zeng X, Wang C, Shi M, Zeng X, **Zhang J**, Wu X, Zhang X, Miao W, Xu P, Guo Z, Zhang J, Chen X. Synthesis, preclinical evaluation and radiation dosimetry of a dual targeting PET tracer [⁶⁸Ga]Ga-FAPI-RGD. *Theranostics*. 2022 Oct 9;12(16):7180-7190. doi: 10.7150/thno.79144. PMID: 36276644; PMCID: PMC9576616.
23. Jiang Y, Liu Q, Wang G, Sui H, Wang R, Wang J, **Zhang J**, Zhu Z, Chen X. Safety and efficacy of peptide receptor radionuclide therapy with ¹⁷⁷Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors. *Theranostics*. 2022 Sep 6;12(15):6437-6445. doi: 10.7150/thno.77219. PMID: 36185603; PMCID: PMC9516233.
24. Schuchardt C, **Zhang J**, Kulkarni HR, Chen X, Müller D, Baum RP. Prostate-Specific Membrane Antigen Radioligand Therapy Using ¹⁷⁷Lu-PSMA I&T and ¹⁷⁷Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer: Comparison of Safety, Biodistribution, and Dosimetry. *J Nucl Med*. 2022 Aug;63(8):1199-1207. doi: 10.2967/jnumed.121.262713. Epub 2021 Dec 9. PMID: 34887335; PMCID: PMC9364353.
25. Zhao L, Pang Y, Wang Y, Chen J, Zhuang Y, **Zhang J**, Zhao L, Sun L, Wu H, Chen X, Lin Q, Chen H. Somatostatin receptor imaging with [⁶⁸Ga]Ga-DOTATATE positron emission tomography/computed tomography (PET/CT) in patients with nasopharyngeal carcinoma. *Eur J Nucl Med Mol Imaging*. 2022 Mar;49(4):1360-1373. doi: 10.1007/s00259-021-05587-7. Epub 2021 Oct 19. PMID: 34665275.
26. Baum RP, Schuchardt C, Singh A, Chantadisai M, Robiller FC, **Zhang J**, Mueller D, Eismant A, Almaguel F, Zboralski D, Osterkamp F, Hoehne A, Reineke U, Smerling C, Kulkarni HR. Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using ¹⁷⁷Lu-FAP-2286: First-in-Humans Results. *J Nucl Med*. 2022 Mar;63(3):415-423. doi: 10.2967/jnumed.120.259192. Epub 2021 Jun 24. PMID: 34168013; PMCID: PMC8978187.

27. Baum RP, **Zhang J**, Schuchardt C, Müller D, Mäcke H. First-in-Humans Study of the SSTR Antagonist ¹⁷⁷Lu-DOTA-LM3 for Peptide Receptor Radionuclide Therapy in Patients with Metastatic Neuroendocrine Neoplasms: Dosimetry, Safety, and Efficacy. *J Nucl Med*. 2021 Nov;62(11):1571-1581. doi: 10.2967/jnumed.120.258889. Epub 2021 Mar 5. PMID: 33674401; PMCID: PMC8612334.
28. Liu Q, Zang J, Sui H, Ren J, Guo H, Wang H, Wang R, Jacobson O, **Zhang J**, Cheng Y, Zhu Z, Chen X. Peptide Receptor Radionuclide Therapy of Late-Stage Neuroendocrine Tumor Patients with Multiple Cycles of ¹⁷⁷Lu-DOTA-EB-TATE. *J Nucl Med*. 2021 Mar;62(3):386-392. doi: 10.2967/jnumed.120.248658. Epub 2020 Aug 21. Erratum in: *J Nucl Med*. 2021 Jul 1;62(7):1015. PMID: 32826319; PMCID: PMC8049339.
29. He K, Chi C, Li D, **Zhang J**, Niu G, Lv F, Wang J, Che W, Zhang L, Ji N, Zhu Z, Tian J, Chen X. Resection and survival data from a clinical trial of glioblastoma multiforme-specific IRDye800-BBN fluorescence-guided surgery. *Bioeng Transl Med*. 2020 Aug 31;6(1):e10182. doi: 10.1002/btm2.10182. PMID: 33532584; PMCID: PMC7823121.